Antidotes in Poisoning : Specific Antidotes
ORENV1 “Renvela powder for oral suspension” 0.8 gm/sachet
適應症 適用於控制接受透析治療的成年慢性腎病患者的高磷血症。
Usual dose:
End stage renal disease – Hemodialysis – Hyperphosphatemia:
(Patients not taking a phosphate binder, serum phosphorus greater than 5.5 and less than 7.5 mg/dL) Initial, 800 mg orally 3 times daily with meals
(Patients not taking a phosphate binder, serum phosphorus greater than or equal to 7.5 mg/dL). Initial 1600 mg orally 3 times a day with meals.
(Switching from sevelamer hydrochloride tablets) Initial, use the same dose in grams; titrate to desired phosphate levels
(Switching between sevelamer carbonate tablets and powder) Initial, use the same dose in grams; titrate to desired phosphate levels
(Switching from calcium acetate, receiving calcium acetate 667 mg per meal) Initial, 800 mg orally per meal
(Switching from calcium acetate, receiving calcium acetate 1334 mg per meal) Initial, 1600 mg orally per meal
(Switching from calcium acetate, receiving calcium acetate 2001 mg per meal) Initial, 2400 mg orally per meal
Dose titration, increase or decrease by 800 mg three times daily with meals at 2 week intervals with a target serum phosphorus goal of 3.5 mg/dL to 5.5 mg/dL
Adverse effect: :
Common: nausea, vomiting.
Serious: bowel obstruction, dysphagia, perforation of intestine